论文部分内容阅读
应用ＬＡＫ／ＩＬ－２单独或与经肝动脉插管化疗药物灌注或栓塞治疗（ＴＡＣＥ）结合，分别通过肿瘤供血动脉、外周静脉或浆膜腔输注等多种途径，治疗肝癌１６例。Ｂ组、Ｃ组均为Ⅱ期与Ⅲ期病例，结合ＴＡＣＥ治疗有效率达６４．３％（９／１４）；而Ａ组２例Ｉ期小肝癌病例，单纯予以肝动脉插管输注ＬＡＫ／ＩＬ－２等治疗无效。提示这种过继免疫治疗不宜单独使用，而在ＴＡＣＥ术后患者免疫功能开始恢复阶段，作为综合治疗的一项措施是十分有益的。
Using LAK/IL-2 alone or in combination with transcatheter arterial infusion chemotherapy or embolization (TACE), 16 cases of hepatocellular carcinoma were treated by various methods such as tumor feeding artery, peripheral vein or serous cavity infusion. Both group B and group C were in stage II and stage III cases. The effective rate of TACE therapy was 64.3% (9/14). In group A, 2 cases of stage I small hepatocellular carcinoma were treated with hepatic artery intubation LAK alone. Treatments such as IL-2 have no effect. It is suggested that this adoptive immunotherapy should not be used alone, but it is very beneficial as a measure of comprehensive treatment that the patient’s immune function begins to recover after TACE.